KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Cash: 2019-2024

Historic Change in Cash for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $23.0 million.

  • AbCellera Biologics' Change in Cash rose 57.19% to -$9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.5 million, marking a year-over-year increase of 5.02%. This contributed to the annual value of $23.0 million for FY2024, which is 109.06% up from last year.
  • Latest data reveals that AbCellera Biologics reported Change in Cash of $23.0 million as of FY2024, which was up 109.06% from -$254.0 million recorded in FY2023.
  • AbCellera Biologics' Change in Cash's 5-year high stood at $586.6 million during FY2020, with a 5-year trough of -$254.0 million in FY2023.
  • Moreover, its 3-year median value for Change in Cash was -$86.5 million (2022), whereas its average is -$105.8 million.
  • Its Change in Cash has fluctuated over the past 5 years, first soared by 20,389.28% in 2020, then slumped by 193.72% in 2023.
  • AbCellera Biologics' Change in Cash (Yearly) stood at $586.6 million in 2020, then crashed by 115.85% to -$93.0 million in 2021, then grew by 6.97% to -$86.5 million in 2022, then slumped by 193.72% to -$254.0 million in 2023, then spiked by 109.06% to $23.0 million in 2024.